[MO33] Mini-Oral Session 33　COVID-19 2

[MO33-1] Limited Increase in Antibody Titers following BNT162b2 for More than 3 Years after Final Dose of Anti-CD20 Antibody

^○Yohei Funakoshi¹, Kimikazu Yakushijin¹, Goh Ohji², Wataru Hojo³, Hironori Sakai³, Marika Watanabe¹, Sakuya Matsumoto¹, Yu Mizutani¹, Akihito Kitao¹, Yoshiharu Miyata⁴, Yasuyuki Saito⁵, Shinichiro Kawamoto⁶, Katsuya Yamamoto¹, Mitsuhiro Ito⁷, Meiko Nishimura¹, Yoshinori Imamura¹, Naomi Kiyota^1,8, Hiroshi Matsuoka⁴, Yasuko Mori⁹, Hironobu Minami^1,8 (1.Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, 2.Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, 3.R&D, Cellspect Co., Ltd., 4.BioResource Center, Kobe University Hospital, 5.Division of Molecular and Cellular Signaling, Kobe University Graduate School of Medicine, 6.Department of Transfusion Medicine and Cell Therapy, Kobe University Hospital, 7.Division of Medical Biophysics, Kobe University Graduate School of Health Sciences, 8.Cancer Center, Kobe University Hospital, 9.Division of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine)